Late-onset attention problems — adult ADHD that wasn't there at 25

The question most people land on is: do I have ADHD? It's not a wrong question. But it might be a partial one.

The diagnostic conversation about adult-onset attention problems has two distinct tracks, and conflating them leads people to the wrong treatment and the wrong conclusions about themselves. The first track is genuine ADHD that was present earlier in life and is only becoming visible now. The second track is executive dysfunction that isn't ADHD but looks a lot like it from the inside — and has a different set of causes and, often, different solutions.

Both are real. Both deserve attention. And the standard clinical response, which tends toward an SSRI-or-stimulant binary, fits neither of them particularly well.

Actual ADHD doesn't originate in your late 30s. The DSM criteria require that symptoms have been present since childhood, even if they were never recognized or diagnosed. For many adults — particularly women, who were historically less likely to be identified as children — the ADHD was always there. What's changed is the scaffolding. At 22, life provides structure: classes with fixed schedules, assignments with deadlines, social routines that organize the day. At 35 or 42, you may be managing a career with high autonomy, a household, possibly children, with far less external structure and far higher executive load. The same underlying ADHD that was manageable with scaffolding becomes visible when the scaffolding comes down.

This is a meaningful distinction because it changes what you're working with. If the underlying neurology was always there, then stimulant medication and ADHD-specific coaching and behavioral strategies are on the table in a way that's evidence-based and appropriate. The conversation with your prescribing provider should include childhood history — not to interrogate you, but because it's clinically relevant. What were you like in school? Did you struggle with sustained attention or organization that you just found ways around? Did you read but rarely finish books? Did you procrastinate severely? These things have always mattered.

The second track is thornier because it's a long list. Executive dysfunction — difficulty sustaining focus, task-switching problems, inability to initiate, working memory lapses — can be downstream of a lot of things that aren't ADHD.

Chronic stress is at the top of the list. The prefrontal cortex, which manages executive function, is exquisitely sensitive to cortisol. Chronic elevation of cortisol — the kind that comes from years of sustained pressure, not acute stress — literally degrades the architecture of the prefrontal cortex. Synaptic connections in that region weaken under long-term cortisol exposure in ways that are measurable in imaging studies. If you have been operating in a sustained stress state for years and your executive function is declining, that's not a personality flaw and it may not be ADHD. It may be the predictable neurological result of what you've been living in.

Sleep architecture loss is next. The prefrontal cortex is the brain region most affected by sleep deprivation, which is both well-established and consistently underweighted in clinical conversations about attention. Slow-wave sleep, which declines with age and with stress, is when working memory resets and the prefrontal cortex consolidates its resources for the following day. If you are not getting adequate deep sleep — whether because of stress, alcohol use, untreated sleep apnea, or simply age-related sleep architecture changes — the executive dysfunction you're experiencing may be substantially sleep-driven. Untreated sleep apnea in particular is a significant and frequently missed contributor to cognitive problems in midlife adults, especially men, and it produces attention and memory symptoms that are nearly indistinguishable from ADHD on a symptom checklist.

The hormonal angle matters in ways that often go unaddressed. Estrogen and testosterone both have receptors in the prefrontal cortex. The cognitive changes that come with perimenopause — and that many women experience as a kind of sudden ADHD they never had before — are well-documented and have a clear mechanistic basis. Declining estrogen reduces dopaminergic tone in the prefrontal cortex, and because dopamine is central to attention and working memory, that drop can produce focus and memory symptoms that feel exactly like ADHD. In men, gradually falling testosterone can contribute to a similar erosion of prefrontal function.

Beyond stress, sleep, and hormones, a handful of conditions round out the executive-dysfunction track because they are common, treatable, and frequently missed. Subclinical hypothyroidism — a thyroid gland producing slightly too little hormone, with a TSH that is elevated but not dramatically so — can blunt processing speed, memory, and concentration well before it produces the classic physical signs that prompt testing, which is why a thyroid panel belongs in any midlife attention workup. Post-viral cognitive effects are another: the brain fog that lingers after COVID-19 and other infections appears to involve neuroinflammation and the same inflammatory signaling that reshapes brain chemistry, and it can present as a sudden, persistent loss of focus in someone who never had attention problems before. Mast cell activation — where immune cells release histamine and inflammatory mediators inappropriately — is less familiar, but the cognitive symptoms it produces, often alongside flushing, gut complaints, and fatigue, can closely resemble ADHD. None of these is what most people reach for when their attention slips, and all of them are worth ruling out before concluding the problem is purely attentional.

This is also the right frame for thinking about whether peptides have any role. Semax and Selank, two short peptides developed in Russia, have early and mostly small-scale research relevance to prefrontal function, stress regulation, and anxiety, and NAD+ precursors are studied for the cellular energy metabolism that suffers under chronic stress and inflammation. None of the three is FDA-approved, none is an ADHD medication, and none undoes cortisol-driven prefrontal changes, restores lost deep sleep, or corrects a thyroid or hormone problem. Their plausible place is as research-stage adjuncts layered on top of a workup that has already identified and begun addressing the upstream cause, and any such use belongs in a conversation with your prescribing provider.

The practical takeaway is that "do I have ADHD?" is rarely the only question worth asking. Attention that was reliable at 25 and isn't now may reflect long-standing ADHD newly unmasked, or it may be the prefrontal cortex responding to cortisol, lost deep sleep, thyroid dysfunction, or shifting hormones — and the distinction shapes everything about what actually helps. A workup that screens those upstream contributors, rather than defaulting to a stimulant-or-SSRI binary, is what gives the symptom its best chance of being addressed at its real source — with peptides like Semax or Selank sitting at most as research-stage adjuncts within that larger picture, never a substitute for finding what changed.